Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET
BioArctic AB (NASDAQ Stockholm: BIOA B) has announced the upcoming release of its second quarter report for April - June 2024 on August 29, 2024, at 08:00 a.m. CET. Following the report's publication, the company will host an audiocast with teleconference at 09:30 CET on the same day. CEO Gunilla Osswald and CFO Anders Martin-Löf will present and discuss the quarterly results, followed by a Q&A session. Investors, analysts, and media are invited to participate via webcast or teleconference. The webcast will be available on-demand on BioArctic's corporate website after the presentation.
BioArctic AB (NASDAQ Stoccolma: BIOA B) ha annunciato il prossimo rilascio del suo rapporto del secondo trimestre per aprile - giugno 2024 il 29 agosto 2024, alle 08:00 CET. Dopo la pubblicazione del rapporto, l'azienda ospiterà un audiocast con teleconferenza alle 09:30 CET
BioArctic AB (NASDAQ Estocolmo: BIOA B) ha anunciado el próximo lanzamiento de su informe del segundo trimestre para abril - junio de 2024 el 29 de agosto de 2024, a las 08:00 CET. Tras la publicación del informe, la empresa llevará a cabo un audiocast con teleconferencia a las 09:30 CET el mismo día. La CEO Gunilla Osswald y el CFO Anders Martin-Löf presentarán y discutirán los resultados trimestrales, seguidos de una sesión de preguntas y respuestas. Inversores, analistas y medios de comunicación están invitados a participar a través de webcast o teleconferencia. El webcast estará disponible bajo demanda en el sitio web corporativo de BioArctic después de la presentación.
BioArctic AB (NASDAQ 스톡홀름: BIOA B)가 2024년 4월 - 6월 2분기 보고서를 2024년 8월 29일, 오전 08:00 CET에 발표할 예정이라고 발표했습니다. 보고서 발행 후 회사는 같은 날 오전 09:30 CET에 오디오 방송 및 전화 회의를 개최합니다. CEO Gunilla Osswald와 CFO Anders Martin-Löf가 분기 결과를 발표하고 논의하며, 이후 질의응답 시간이 이어집니다. 투자자, 분석가 및 언론인들은 웹캐스트 또는 전화 회의를 통해 참여할 수 있습니다. 웹캐스트는 발표 후 BioArctic의 기업 웹사이트에서 주문형으로 제공됩니다.
BioArctic AB (NASDAQ Stockholm: BIOA B) a annoncé la prochaine publication de son rapport du deuxième trimestre pour avril - juin 2024 le 29 août 2024, à 08h00 CET. À la suite de la publication du rapport, la société organisera un audiocast avec téléconférence à 09h30 CET le même jour. La PDG Gunilla Osswald et le CFO Anders Martin-Löf présenteront et discuteront des résultats trimestriels, suivis d'une séance de questions-réponses. Les investisseurs, les analystes et les médias sont invités à participer via webcast ou téléconférence. Le webcast sera disponible à la demande sur le site web de l'entreprise BioArctic après la présentation.
BioArctic AB (NASDAQ Stockholm: BIOA B) hat die bevorstehende Veröffentlichung seines Quartalsberichts für April - Juni 2024 für den 29. August 2024, um 08:00 Uhr CET angekündigt. Nach der Veröffentlichung des Berichts wird das Unternehmen am selben Tag um 09:30 Uhr CET eine Audiokonferenz durchführen. CEO Gunilla Osswald und CFO Anders Martin-Löf werden die Quartalszahlen präsentieren und diskutieren, gefolgt von einer Fragerunde. Investoren, Analysten und Medienvertreter sind eingeladen, über Webcast oder Telefonkonferenz teilzunehmen. Der Webcast wird nach der Präsentation auf der Unternehmenswebsite von BioArctic on-demand verfügbar sein.
- None.
- None.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on August 29, at 09:30 CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, will present and comment on the second quarter report, followed by a Q&A-session.
If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions.
Webcast: https://ir.financialhearings.com/bioarctic-q2-report-2024/register
If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.financialhearings.com/teleconference/?id=50047207
The webcast will also be available on demand on BioArctic's corporate website https://www.bioarctic.se/en/section/investors/presentations/after the presentation.
For more information, please contact:
Oskar Bosson, VP Communications and Investor Relations, BioArctic AB
E-mail: oskar.bosson@bioarctic.se
Tel: + 46 704 10 71 80
This information was submitted for publication at 08:30 a.m. CET on August 19, 2024.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on treatments that can delay or stop the progression of neurodegenerative diseases. The company invented LEQEMBI® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.se.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET |
View original content:https://www.prnewswire.com/news-releases/invitation-to-presentation-of-bioarctics-second-quarter-report-for-april---june-2024-on-august-29-at-9-30-am-cet-302225132.html
SOURCE BioArctic
FAQ
When will BioArctic (BIOA) release its Q2 2024 financial results?
How can I participate in BioArctic's (BIOA) Q2 2024 earnings call?
Who will be presenting BioArctic's (BIOA) Q2 2024 financial results?
Will there be a Q&A session during BioArctic's (BIOA) Q2 2024 earnings call?
